Schubprophylaxe mit Interferonen und Glatiramerazetat

Zusammenfassung

Nach den Empfehlungen der Multiple Sklerose-Therapie-Konsensusgruppe (MSTKG) sind Beta-Interferone und Glatiramerazetat für die immunmodulatorische Basistherapie akzeptiert und empfohlen. Die Wirkung auf Schubhäufigkeit, Progression der Behinderung und insbesondere die Veränderungen im MRT gilt als erwiesen und auch die Langzeitgabe wird akzeptiert. Die Toleranz der Interferone wird durch mögliche Hautreaktionen und grippeähnliche Symptome eingeschränkt, wobei viele Anstrengungen unternommen worden sind, eine bessere Verträglichkeit zu erreichen. Unabhängig davon ist das Auftreten neutralisierender Antikörper (NAK) in einem bislang nicht eindeutig belegbaren Anteil für einen möglichen Wirkungsverlust von Interferonen verantwortlich. Die Nebenwirkungen vom Glatiramerazetat dürfen als sehr viel geringfügiger betrachtet werden, sie beziehen sich auf Hautreaktionen und die subakute Post-Injektionsreaktion.

Summary

According to the Multiple Sclerosis Therapy Consensus Group (MSTCG) recommendations beta-interferons and glatiramer acetate are well accepted for immunomodulatory basic therapy. Relapse rate, progression of disease and changes in MRI are effectively treated also in longterm applications. Interferons are well tolerated over the time but often injections are followed by skin reactions and by „flu like“ symptoms. Some efforts have been done to improve tolerability. The production of high titre neutralizing antibodies (NAB) is probably responsible for a reduction of clinical effect of interferons. Side effects of glatiramer acetate are rather negligible. Skin reactions and a subacute postinjection reaction can be observed.

Schlüsselwörter

Multiple Sklerose - Immuntherapie - Immunmodulation

Keywords

Multiple Sclerosis - immunotherapy - immunomodulation

• Literatur

• 1 Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L. High-dose, frequently administered interferon beta therapy for relapsing –remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. J Neurol Sci. 2004; 222: 13-9.
• 2 Barkhof F, van WaesbergheJH, Filippi M, Yousry T, Miller DH, Hahn D, Thompson AJ, Kappos L, Brex P, Pozzilli C, Polman CH. European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001; 124: 1396-402.
• 3 Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR. Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; May 19; 357: 1576-82.
• 4 Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O. Effect of early interferon treatment on conversion to definite multiple sclerosis: The ETOMS study-4 Years results. Multiple Sclerosis 2002; 8 (Suppl. 01) S8.
• 5 Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo- controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-7.
• 6 Filippi M. et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into „black holes“. Neurology 2001; 57: 731-3.
• 7 Ford G. ECTRIMS 2003. Abstracts of the 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. September 17–20, 2003, Milan, Italy. Mult Scler 2003; 9 (Suppl. 01) S1-162.
• 8 Francis GS. Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 2004; 251 (Suppl. 05) V42-V45.
• 9 Gold R, Hartung HP. Aktueller Therapieüberblick und zukünftige Therapiestrategien der Multiplen Sklerose. Nervenheilkunde 2003; 22 (Suppl. 01) S15-S24.
• 10 Khan O. Interferon-beta therapy for MS: the dilemma of having choices. J Neurol Sci 2004; 222 (1-2): 1.
• 11 Metz LM, Patten SB, Archibald CJ, Bakker JI, Harris CJ, Patry DG, Bell RB, Yeung M, Murphy WF, Stoian CA, Billesberger K, Tillotson L, Peters S, McGowan D. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry 2004; 75 (07) 1045-7.
• 12 MSTCG. Escalating immunotherapy of multiple sclerosis – New aspects and practical applications. J Neurol 2004; 251: 1329-39.
• 13 Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then BerghF, Dose T, Wekerle H, Hohlfeld R. Multiple sclerosis: comparison of copolymer-1– reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci 2000; 97 (13) 7452-7.
• 14 Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dahlke F, Gasperini C. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 2002; 249 (01) 50-6.
• 15 Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004; 62 (08) 1432-4.